In vivo beta-cell imaging with VMAT 2 ligands - current state-of-the-art and future perspectives

Current Pharmaceutical Design

Volumn 16, Issue 14, 2010, Pages 1568-1581

  Veluthakal, Rajakrishnan ^a   Harris, Paul ^a  

^a Columbia University ^*  (United States)

Author keywords

Beta cell mass; Diabetes; DTBZ; PET; VMAT2

Indexed keywords

BIOLOGICAL MARKER; C PEPTIDE; DOPAMINE; HEMOGLOBIN A1C; INSULIN; RADIOLIGAND; VESICULAR MONOAMINE TRANSPORTER 2; LIGAND; SLC18A2 PROTEIN, HUMAN; VESICULAR MONOAMINE TRANSPORTER;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DATA ANALYSIS; DIABETES MELLITUS; DOPAMINE BRAIN LEVEL; HISTOGRAM; HUMAN; HUMAN CELL; IMAGING; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; LIGAND BINDING; NONHUMAN; PANCREAS ISLET BETA CELL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; SIGNAL NOISE RATIO; DISEASE COURSE; METABOLISM; PANCREAS ISLET; PATHOLOGY; REVIEW; SCINTISCANNING;

BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; HUMANS; ISLETS OF LANGERHANS; LIGANDS; POSITRON-EMISSION TOMOGRAPHY; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 77956216696     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210791164180     Document Type: Article

References (75)

1. Group. BDW. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95.
2. http://www.cancer.gov/dictionary/?CdrID=45618.
3. Gepts W. Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes 1965; 14: 619-33.
4. Gepts W, Lecompte PM. The pancreatic islets in diabetes. Am J Med 1981; 70: 105-15.
5. Saito K, Yaginuma N, Takahashi T. Differential volumetry of A, B and D cells in the pancreatic islets of diabetic and nondiabetic subjects. Tohoku J Exp Med 1979; 129: 273-83.
6. Shi ZD, Wu H, Ruddy B, Griffiths GL. Imaging probe development center: a national institutes of health core synthesis resource for imaging probes. J Biomed Opt 2007; 12: 051502.
7. Simpson NR, Souza F, Witkowski P, Maffei A, Raffo A, Herron A, et al. Visualizing pancreatic beta-cell mass with [11C]DTBZ. Nucl Med Biol 2006; 33: 855-64.
8. Sundsten T, Ortsater H. Proteomics in diabetes research. Mol Cell Endocrinol 2009; 297: 93-103.
9. Ueberberg S, Meier JJ, Waengler C, Schechinger W, Dietrich JW, Tannapfel A, et al. Generation of novel single-chain antibodies by phage-display technology to direct imaging agents highly selective to pancreatic {beta}- or {alpha}-cells in vivo. Diabetes 2009; 58(10): 2324-34.
10. Wenzlau JM, Frisch LM, Gardner TJ, Sarkar S, Hutton JC, Davidson HW. Novel antigens in type 1 diabetes: the importance of ZnT8. Curr Diab Rep 2009; 9: 105-12.
11. Samli KN, McGuire MJ, Newgard CB, Johnston SA, Brown KC. Peptide-mediated targeting of the islets of Langerhans. Diabetes 2005; 54: 2103-8.
12. Kutlu B, Burdick D, Baxter D, Rasschaert J, Flamez D, Eizirik DL, et al. Detailed transcriptome atlas of the pancreatic beta cell. BMC Med Genomics 2009; 2: 3.
13. Quayum N, Kutchma A, Sarkar SA, Juhl K, Gradwohl G, Mellitzer G, et al. GeneSpeed beta cell: an online genomics data repository and analysis resource tailored for the islet cell biologist. Exp Diabetes Res 2008; 2008: 312060.
14. Jongeneel CV, Delorenzi M, Iseli C, Zhou D, Haudenschild CD, Khrebtukova I, et al. An atlas of human gene expression from massively parallel signature sequencing (MPSS). Genome Res 2005; 15: 1007-14.
15. Maffei A, Liu Z, Witkowski P, Moschella F, Del Pozzo G, Liu E, et al. Identification of tissue-restricted transcripts in human islets. Endocrinology 2004; 145: 4513-21.
16. Goland R, Freeby M, Parsey R, Saisho Y, Kumar D, Simpson N, et al. 11C-dihydrotetrabenazine PET of the pancreas in subjects with long-standing type 1 diabetes and in healthy controls. J Nucl Med 2009; 50: 382-9.
17. Kung HF, Lieberman BP, Zhuang ZP, Oya S, Kung MP, Choi SR, et al. In vivo imaging of vesicular monoamine transporter 2 in pancreas using an (18)F epoxide derivative of tetrabenazine. Nucl Med Biol 2008; 35: 825-37.
18. Witkowski P, Sondermeijer H, Hardy M, Woodland D, Lee K, Bhagat G, et al. Islet grafting and imaging in a bioengineered intramuscular space. Transplantation 2009; 88(9): 1065-74.
19. Singhal T, Labaree D, Ropchan J, Nabulsi N, Weinzimmer D, Treadway J, et al. Evaluation of [C-11]DTBZ-PET for estimation of pancreatic beta cell mass (BCM) in a rat model of diabetes. J Nucl Med 2008; 49 (Suppl 1): 317.
20. Meier JJ, Butler AE, Saisho Y, Monchamp T, Galasso R, Bhushan A, et al. Beta-cell replication is the primary mechanism subserving the postnatal expansion of beta-cell mass in humans. Diabetes 2008; 57: 1584-94.
21. Atouf F, Czernichow P, Scharfmann R. Expression of neuronal traits in pancreatic beta cells. Implication of neuron-restrictive silencing factor/repressor element silencing transcription factor, a neuron-restrictive silencer. J Biol Chem 1997; 272: 1929-34.
22. Bernal-Mizrachi E, Cras-Meneur C, Ohsugi M, Permutt MA. Gene expression profiling in islet biology and diabetes research. Diabetes Metab Res Rev 2003; 19: 32-42.
23. Weihe E, Eiden LE. Chemical neuroanatomy of the vesicular amine transporters. FASEB J 2000; 14: 2435-49.
24. Weihe E, Schafer MK, Erickson JD, Eiden LE. Localization of vesicular monoamine transporter isoforms (VMAT1 and VMAT2) to endocrine cells and neurons in rat. J Mol Neurosci 1994; 5: 149-64.
25. Erickson JD, Schafer MK, Bonner TI, Eiden LE, Weihe E. Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc Natl Acad Sci USA 1996; 93: 5166-71.
26. Ahren B. Autonomic regulation of islet hormone secretion-- implications for health and disease. Diabetologia 2000; 43: 393-410.
27. Anlauf M, Eissele R, Schafer MK, Eiden LE, Arnold R, Pauser U, et al. Expression of the two isoforms of the vesicular monoamine transporter (VMAT1 and VMAT2) in the endocrine pancreas and pancreatic endocrine tumors. J Histochem Cytochem 2003; 51: 1027-40.
28. Saisho Y, Harris PE, Butler AE, Galasso R, Gurlo T, Rizza RA, et al. Relationship between pancreatic vesicular monoamine transporter 2 (VMAT2) and insulin expression in human pancreas. J Mol Histol 2008; 39: 543-51.
29. Baetens D, De Mey J, Gepts W. Immunohistochemical and ultrastructural identification of the pancreatic polypeptideproducing cell (PP-cell) in the human pancreas. Cell Tissue Res 1977; 185: 239-46.
30. Rahier J, Wallon J, Gepts W, Haot J. Localization of pancreatic polypeptide cells in a limited lobe of the human neonate pancreas: remnant of the ventral primordium? Cell Tissue Res 1979; 200: 359-66.
31. Rahier J, Wallon J, Loozen S, Lefevre A, Gepts W, Haot J. The pancreatic polypeptide cells in the human pancreas: the effects of age and diabetes. J Clin Endocrinol Metab 1983; 56: 441-4.
32. Baetens D, Malaisse-Lagae F, Perrelet A, Orci L. Endocrine pancreas: three-dimensional reconstruction shows two types of islets of langerhans. Science 1979; 206: 1323-5.
33. Herrera PL. Defining the cell lineages of the islets of Langerhans using transgenic mice. Int J Dev Biol 2002; 46: 97-103.
34. Delghingaro-Augusto V, Nolan CJ, Gupta D, Jetton TL, Latour MG, Peshavaria M, et al. Islet beta cell failure in the 60% pancreatectomised obese hyperlipidaemic Zucker fatty rat: severe dysfunction with altered glycerolipid metabolism without steatosis or a falling beta cell mass. Diabetologia 2009; 52: 1122-32.
35. Goodison S, Kenna S, Ashcroft SJ. Control of insulin gene expression by glucose. Biochem J 1992; 285 (Pt 2): 563-8.
36. Wang H, Kouri G, Wollheim CB. ER stress and SREBP-1 activation are implicated in beta-cell glucolipotoxicity. J Cell Sci 2005; 118: 3905-15.
37. Freeby M, Goland R, Ichise M, Maffei A, Leibel R, Harris P. VMAT2 quantitation by PET as a biomarker for beta-cell mass in health and disease. Diabetes Obes Metab 2008; 10 (Suppl 4): 98-108.
38. Poitout V, Hagman D, Stein R, Artner I, Robertson RP, Harmon JS. Regulation of the insulin gene by glucose and fatty acids. J Nutr 2006; 136: 873-6.
39. Bacha F, Gungor N, Arslanian SA. Measures of beta-cell function during the oral glucose tolerance test, liquid mixed-meal test, and hyperglycemic clamp test. J Pediatr 2008; 152: 618-21.
40. Liu E, Herscovitch P, Barker C, Harlan D. C-11-DTBZ PET scanning: its potential for measuring beta-cell mass in vivo. Diabetes 2007; A83-3.
41. Williams AJ, Chau W, Callaway MP, Dayan CM. Magnetic resonance imaging: a reliable method for measuring pancreatic volume in Type 1 diabetes. Diabet Med 2007; 24: 35-40.
42. Boileau I, Rusjan P, Houle S, Wilkins D, Tong J, Selby P, et al. Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: Is VMAT2 a stable dopamine neuron biomarker? J Neurosci 2008; 28: 9850-6.
43. De La Fuente-Fernandez R, Furtado S, Guttman M, Furukawa Y, Lee CS, Calne DB, et al. VMAT2 binding is elevated in doparesponsive dystonia: visualizing empty vesicles by PET. Synapse 2003; 49: 20-8.
44. Raffo A, Hancock K, Polito T, Xie Y, Andan G, Witkowski P, et al. Role of vesicular monoamine transporter type 2 in rodent insulin secretion and glucose metabolism revealed by its specific antagonist tetrabenazine. J Endocrinol 2008; 198: 41-9.
45. Rubi B, Ljubicic S, Pournourmohammadi S, Carobbio S, Armanet M, Bartley C, et al. Dopamine D2-like receptors are expressed in pancreatic beta cells and mediate inhibition of insulin secretion. J Biol Chem 2005; 280: 36824-32.
46. Cselenyi Z, Olsson H, Halldin C, Gulyas B, Farde L. A comparison of recent parametric neuroreceptor mapping approaches based on measurements with the high affinity PET radioligands [11C]FLB 457 and [11C]way 100635. Neuroimage 2006; 32: 1690-708.
47. Kim J, Cai W, Feng D, Eberl S. Segmentation of VOI from multidimensional dynamic PET images by integrating spatial and temporal features. IEEE Trans Inf Technol Biomed 2006; 10: 637-46.
48. Guo H, Renaut R, Chen K, Reiman E. Clustering huge data sets for parametric PET imaging. Biosystems 2003; 71: 81-92.
49. Pick A, Clark J, Kubstrup C, Levisetti M, Pugh W, Bonner-Weir S, et al. Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes 1998; 47: 358-64.
50. Inuwa IM, El Mardi AS. Correlation between volume fraction and volume-weighted mean volume, and between total number and total mass of islets in post-weaning and young Wistar rats. J Anat 2005; 206: 185-92.
51. Glatt CE, Wahner AD, White DJ, Ruiz-Linares A, Ritz B. Gain-offunction haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women. Hum Mol Genet 2006; 15: 299-305.
52. Goswami R, Ponde DE, Kung MP, Hou C, Kilbourn MR, Kung HF. Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters. Nucl Med Biol 2006; 33: 685-94.
53. Kilbourn MR, Hockley B, Lee L, Hou C, Goswami R, Ponde DE, et al. Pharmacokinetics of [(18)F]fluoroalkyl derivatives of dihydrotetrabenazine in rat and monkey brain. Nucl Med Biol 2007; 34: 233-7.
54. Kung M, Lieberman B, Hou C, Ponde D, Goswami R, Skovronsky D, Deng S, et al. F-18(+)FP-DTBZ: An investigational PET ligand for measuring beta cell mass in the pancreas. J Nucl Med 2007; 48 114p.
55. Koeppe RA, Frey KA, Kuhl DE, Kilbourn MR. Assessment of extrastriatal vesicular monoamine transporter binding site density using stereoisomers of [11C]dihydrotetrabenazine. J Cereb Blood Flow Metab 1999; 19: 1376-84.
56. Logan J. Graphical analysis of PET data applied to reversible and irreversible tracers. Nucl Med Biol 2000; 27: 661-70.
57. Albin RL, Koeppe RA, Bohnen NI, Nichols TE, Meyer P, Wernette K, et al. Increased ventral striatal monoaminergic innervation in Tourette syndrome. Neurology 2003; 61: 310-5.
58. Bohnen NI, Albin RL, Koeppe RA, Wernette KA, Kilbourn MR, Minoshima S, et al. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab 2006; 26: 1198-212.
59. Bohnen NI, Koeppe RA, Meyer P, Ficaro E, Wernette K, Kilbourn MR, et al. Decreased striatal monoaminergic terminals in Huntington disease. Neurology 2000; 54: 1753-9.
60. Kilbourn MR, Frey KA, Vander Borght T, Sherman PS. Effects of dopaminergic drug treatments on in vivo radioligand binding to brain vesicular monoamine transporters. Nucl Med Biol 1996; 23: 467-71.
61. Vander Borght T, Kilbourn M, Desmond T, Kuhl D, Frey K. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol 1995; 294: 577-83.
62. Vilpoux C, Leroux-Nicollet I, Naudon L, Raisman-Vozari R, Costentin J. Reserpine or chronic paroxetine treatments do not modify the vesicular monoamine transporter 2 expression in serotonin-containing regions of the rat brain. Neuropharmacology 2000; 39: 1075-82.
63. Wilson JM, Kish SJ. The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat. J Neurosci 1996; 16: 3507-10.
64. Barg S. Mechanisms of exocytosis in insulin-secreting B-cells and glucagon-secreting A-cells. Pharmacol Toxicol 2003; 92: 3-13.
65. Cline G, Carson RE, Ding YS, Huang H, Weinzimmer DP, Jakoski A, et al. Islet-selectivity of G-protein coupled receptor (GPCR) ligands evaluated for PET imaging. Diabetes 2008; 58 (Suppl): 156.
66. Xie Y, Raffo A, Ichise M, Deng S, Harris PE, Landry DW. Novel hypoglycemic dihydropyridones serendipitously discovered from O-versus C-alkylation in the synthesis of VMAT2 antagonists. Bioorg Med Chem Lett 2008; 18: 5111-4.
67. Harris PE, Ferrara C, Barba P, Polito T, Freeby M, Maffei A. VMAT2 gene expression and function as it applies to imaging betacell mass. J Mol Med 2008; 86: 5-16.
68. Murthy R, Harris P, Simpson N, Van Heertum R, Leibel R, Mann JJ, et al. Whole body [(11)C]-dihydrotetrabenazine imaging of baboons: biodistribution and human radiation dosimetry estimates. Eur J Nucl Med Mol Imaging 2008; 35(4): 790-7.
69. Inabnet WB, 3rd, Milone L, Korner J, Durak E, Ahmed L, Pomrantz J, et al. A rodent model of metabolic surgery for study of type 2 diabetes and positron emission tomography scanning of beta cell mass. Surg Obes Relat Dis 2009; 5: 212-7.
70. Zhu L, Liu J, Kung HF. Synthesis and evaluation of 2-aminodihydrotetrabenzine derivatives as probes for imaging vesicular monoamine transporter-2. Bioorg Med Chem Lett 2009; 19: 5026-8.
71. Gubernator NG, Zhang H, Staal RG, Mosharov EV, Pereira DB, Yue M, et al. Fluorescent false neurotransmitters visualize dopamine release from individual presynaptic terminals. Science 2009; 324: 1441-4.
72. Chen G, Yee DJ, Gubernator NG, Sames D. Design of optical switches as metabolic indicators: new fluorogenic probes for monoamine oxidases (MAO A and B). J Am Chem Soc 2005; 127: 4544-5.
73. Huber JD. Diabetes, cognitive function, and the blood-brain barrier. Curr Pharm Des 2008; 14(16): 1594-600.
74. Penberthy WT. Nicotinamide adenine dinucleotide biology and disease. Curr Pharm Des 2009; 15(1): 1-2.
75. Thompson CS. Animal models of diabetes mellitus: relevance to vascular complications. Curr Pharm Des 2008; 14(4): 309-24.